In some contrast, levels of CD34 + CD309+ cells in JIA patients treated or not with etancercept were similar (0.005% [0.002%-0.07%] vs. 0.04% [0.014%-0.11%]; p = 0.08, respectively; Figure 1b). The gene discussed is CD34; the disease is juvenile idiopathic arthritis.